MediciNova Inc. (MNOV)
1.46
-0.04 (-2.67%)
At close: Mar 28, 2025, 3:57 PM
1.45
-0.68%
After-hours: Mar 28, 2025, 04:05 PM EDT
-2.67% (1D)
| Bid | 1.43 |
| Market Cap | 71.61M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.86B |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -6.35 |
| Forward PE | -3.96 |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 13,548 |
| Avg. Volume (20D) | 19,661 |
| Open | 1.49 |
| Previous Close | 1.50 |
| Day's Range | 1.44 - 1.50 |
| 52-Week Range | 1.12 - 2.55 |
| Beta | 0.73 |
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced periphera...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2006
Employees 13
Stock Exchange NASDAQ
Ticker Symbol MNOV
Website https://www.medicinova.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MNOV stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 516.44% from the latest price.
Stock Forecasts3 months ago
+14.98%
MediciNova shares are trading higher after D. Bora...
Unlock content with
Pro Subscription
4 months ago
+49.02%
MediciNova shares are trading higher after the company announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled.
